Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy. (Q38204290)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

4 references

1 September 2020

14 September 2020

28 January 2021

8 February 2021

Molecularly targeting the PI3K-Akt-mTOR pathway can sensitize cancer cells to radiotherapy and chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

Adaptive radiation therapy

14 March 2020

main subject

0 references

AKT serine/threonine kinase 1

1 reference

1 September 2020

1 reference

14 September 2020

Serine/threonine-protein kinase TOR

1 reference

28 January 2021

1 reference

8 February 2021

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jiqiang Zhang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Ziwen Wang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

11 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

Cellular & Molecular Biology Letters

14 March 2020

1 June 2014

4 references

1 September 2020

14 September 2020

28 January 2021

8 February 2021

5 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 September 2020

14 September 2020

28 January 2021

8 February 2021

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

page(s)

233-242

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2478/s11658-014-0191-7

14 March 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

p53 in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Structure, function, and mechanism of ribonucleotide reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Cell-cycle checkpoints and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Regulation of TORC1 by Rag GTPases in nutrient response

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Expanded roles of the Fanconi anemia pathway in preserving genomic stability

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

mTOR and the control of whole body metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Restoration of p53 to limit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Structure of the FANCI-FANCD2 Complex: Insights into the Fanconi Anemia DNA Repair Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Molecular mechanisms underlying RB protein function

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

How the fanconi anemia pathway guards the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

mTOR in aging, metabolism, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Emerging roles of E2Fs in cancer: an exit from cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions in poly(A)-dependent translation

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Development of PI3K inhibitors: lessons learned from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

TOR signaling is a determinant of cell survival in response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

Fanconi anemia: a disorder defective in the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

PTEN function in normal and neoplastic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-014-0191-7

PTEN mutation: many birds with one stone in tumorigenesis.

21 January 2018

1 reference

12 December 2020

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

12 December 2020

SnapShot: mTOR signaling

1 reference

12 December 2020

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

1 reference

12 December 2020

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

1 reference

12 December 2020

The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3

1 reference

12 December 2020

10.2478/S11658-014-0191-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

14 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

24728800

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24728800%20AND%20SRC:MED&resulttype=core&format=json